Edition:
India

Compugen Ltd (CGEN.OQ)

CGEN.OQ on NASDAQ Stock Exchange Global Market

3.04USD
14 Dec 2018
Change (% chg)

$-0.12 (-3.80%)
Prev Close
$3.16
Open
$3.20
Day's High
$3.20
Day's Low
$2.99
Volume
39,154
Avg. Vol
34,536
52-wk High
$5.00
52-wk Low
$2.45

Latest Key Developments (Source: Significant Developments)

Compugen Q3 Loss Per Share $0.05
Wednesday, 7 Nov 2018 

Nov 7 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS THIRD QUARTER 2018 RESULTS.Q3 LOSS PER SHARE $0.05.Q3 REVENUE $7.8 MILLION.Q3 EARNINGS PER SHARE VIEW $-0.20, REVENUE VIEW $0.00 -- THOMSON REUTERS I/B/E/S.  Full Article

Compugen Announces Clinical Milestone Payment In Cancer Immunotherapy Collaboration With Bayer
Thursday, 20 Sep 2018 

Sept 20 (Reuters) - Compugen Ltd ::COMPUGEN ANNOUNCES CLINICAL MILESTONE PAYMENT IN CANCER IMMUNOTHERAPY COLLABORATION WITH BAYER FOLLOWING DOSING OF FIRST PATIENT IN BAY 1905254 PHASE 1 TRIAL.COMPUGEN LTD - UNDER TERMS OF COLLABORATION AND LICENSE AGREEMENT, CO IS ENTITLED TO A MILESTONE PAYMENT OF $7.8 MILLION AT FIRST PATIENT DOSING.  Full Article

Compugen's Q2 Loss Per Share $0.19
Wednesday, 1 Aug 2018 

Aug 1 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.19.  Full Article

Compugen Announces FDA Clearance Of IND Application For COM701, A First-In-Class Immuno-Oncology Therapeutic Antibody
Monday, 2 Jul 2018 

July 2 (Reuters) - Compugen Ltd ::COMPUGEN ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR COM701, A FIRST-IN-CLASS IMMUNO-ONCOLOGY THERAPEUTIC ANTIBODY.  Full Article

Compugen Reports Q1 Revenue Of $10 Million
Wednesday, 9 May 2018 

May 9 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS FIRST QUARTER 2018 RESULTS.Q1 EARNINGS PER SHARE $0.00.Q1 REVENUE $10 MILLION.  Full Article

COMPUGEN REPORTS Q3 LOSS PER SHARE $0.19
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Compugen Ltd ::COMPUGEN REPORTS THIRD QUARTER 2017 RESULTS.Q3 LOSS PER SHARE $0.19.‍AS OF SEPTEMBER 30, 2017, CASH AND CASH RELATED ACCOUNTS TOTALED $38.5 MILLION, COMPARED WITH $61.5 MILLION AS OF DECEMBER 31, 2016​.  Full Article

Compugen to initiate manufacturing of COM902
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Compugen Ltd :Compugen Ltd - ‍advancing COM902 into manufacturing in anticipation of filing an investigational new drug (IND) application in 2019​.Compugen Ltd - ‍entered into process development and manufacturing service agreement with Bayer Healthcare LLC (Bayer) to produce COM902.Compugen Ltd - ‍working towards filing IND for COM902 in 2019​.  Full Article

Photo

Bristol-Myers to invest in Compugen, collaborate in clinical trials

TEL AVIV Bristol-Myers Squibb Co and Israel's Compugen said on Thursday they will collaborate in clinical trials for patients with advanced solid tumors.